Table 2 Characteristics of the study population
Age (years) | 58 | (51,67) |
Female gender | 39 | (17.4) |
BMI (kg/m2) | 26 | (24.4,28.7) |
Waist circumference (cm) | 100 | (94,107) |
Current smoking | 109 | (48.7) |
Previous medical history | ||
Hypertension | 58 | (25.9) |
Hyperlipidemia | 20 | (8.9) |
Myocardial infarction | 16 | (7.1) |
Acute phase | ||
Leukocyte count (× 109/l) | 10.2 | (8.5,12.4) |
Ischemic time (min)a | 219 | (139,382) |
HbA1c (%) | 5.5 | (5.3,5.8) |
Plasma glucose, start of OGTT (mmol/L) | 5.3 | (4.9,5.9) |
Plasma glucose, end of OGTT (mmol/L) | 7.3 | (5.9,8.8) |
AGR | 105 | (46.9) |
Peak Troponin T (μg/L) | 4.7 | (2.4,9.0) |
Medication at hospital discharge | ||
Acetylsalicylic acid | 224 | (100) |
Clopidogrel | 222 | (99.1) |
Statins | 221 | (98.7) |
Betablockers | 181 | (80.8) |
ACE-inhibitors | 36 | (16.1) |
ATII antagonists | 18 | (8.0) |
After 3 months | ||
Plasma glucose, start of OGTT (mmol/L) | 5.2 | (4.8,5.6) |
Plasma glucose, end of OGTT (mmol/L) | 5.4 | (4.5,7.1) |
AGR | 50 | (24.9) |
Infarct size, %b | 14 | (0,29) |
LVEF, %b | 64 | (56,70) |